


Financial / Non-Financial Highlights

(For the fiscal years as of / ended March 31)

Financial Highlights

Net Sales


7% DOWN (YoY)



Foreign exchange influences placed downward pressure on net sales to the tune of ¥74.3 billion, and net sales decreased 7% year on year as a result. If the impacts of foreign exchange influences are excluded, net sales increased 2% due to positive growth in the Medical Business and the Scientific Solutions Business.

Operating Income

27% DOWN (YoY)




Although full-year operating income was achieved in the Imaging Business for the first time in seven years, consolidated operating income was down 27% year on year due to a ¥30.1 billion reduction attributable to foreign exchange influences. If the impacts of foreign exchange influences are excluded, operating income increased 2% year on year.

EBITDA

16% DOWN (YoY)

EBITDA Margin

1.8 points DOWN (YoY)




Earnings before interest, taxes, depreciation, and amortization (EBITDA) decreased 16% due to the decline in operating income. The EBITDA margin was 17.4%.

Net Income (Loss)

25% UP (YoY)

ROE

2.3 points UP (YoY)




Despite the decrease in operating income, net income reached a new record high for the second consecutive year due to the recording of ¥25.1 billion in gain on available-for-sale securities, net. Return on equity (ROE) was 19.3%, greatly exceeding the target of 15%.

Total Net Assets

12% UP (YoY)

Equity Ratio


5.1 points UP (YoY)



The equity ratio rose 5.1 percentage points due to higher retained earnings resulting from record-breaking net income and reduced interest-bearing debt.

Free Cash Flows (FCF)

¥86.2 billion UP (YoY)




Net cash provided by operating activities amounted to ¥90.2 billion, which, combined with proceeds from sales and redemption of investment securities of ¥42.2 billion, resulted in positive free cash flow of ¥81.9 billion.

Net Income (Loss) per Share

¥45.57 UP (YoY)

Total Equity per Share

¥135.72 UP (YoY)




Net income per share amounted to ¥228.47 as a result of record-breaking net income. Total equity per share increased ¥135.72 year on year.

Cash Dividends per Share

¥11 UP (YoY)

Payout Ratio


3.0 points UP (YoY)



In fiscal 2017, cash dividends per share were raised by ¥11 year on year, to ¥28 per share. The dividend payout ratio was 12.3%. (The Company adopts the policy of increasing cash dividend payments to target a total return ratio of 30%.)

R&D Expenditures 3% DOWN (YoY)


Percentage of Net Sales 0.5 point UP (YoY)



R&D expenditures were conducted in fields featuring growth potential, primarily in the Medical Business. One investment target was the VISERA ELITE II surgical endoscopy system that was launched in certain regions in March 2017. We conduct investments targeting a ratio of R&D expenditures to net sales of between 9% and 10%.

Capital Expenditures 23% DOWN (YoY)


Depreciation and Amortization 12% UP (YoY)



Capital expenditures amounted to ¥49.3 billion and were primarily directed at bolstering production equipment and upgrading existing facilities at the Aomori and Vietnam factories, which manufacture endotherapy devices for the Medical Business. Depreciation and amortization increased 12% year on year as result of the start of operations at a flagship endoscope factory at which expansion work was completed during fiscal 2016.


Non-Financial Highlights

Greenhouse Gas (GHG) Emissions*1,2 Increased 2.4% (YoY)




The majority of the energy consumed by Olympus is in the form of electricity. In order to reduce electricity use, we are promoting energy-saving activities in daily operations, utilizing renewable energy, implementing eco-friendly measures when constructing new buildings, and developing manufacturing technologies that use less energy and resources. In this manner, the Company is working to reduce the environmental impact of its manufacturing operations.

Transportation-Related GHG Emissions Reduced 9.0% (YoY)




Olympus is working to reduce CO₂ emissions from logistics by lowering transportation loads through the reduction of product and packaging weights, improving transportation efficiency, and accelerating the modal shift toward transportation methods that produce less CO₂.

Water Use*3 Reduced 6.1% (YoY)



Olympus uses water to wash product components. To reduce water use, the Company is continuously developing production methods that require less water and inspecting equipment to prevent leakage. We are also working to minimize the environmental impact by monitoring wastewater treatment facilities and conducting appropriate maintenance and by managing the quality of wastewater.

Waste Emissions*3 Increased 5.2% (YoY)



Olympus continues to pursue higher resource productivity in its manufacturing activities through efforts at various levels. These efforts include reduction in disposal at landfills, the improvement of recycling ratios, the reduction of processing losses, and the design of products to minimize waste.

*1. Scope: Olympus Corporation and its domestic and overseas subsidiaries (excluding those of small scale)

*2. Olympus reports in the following categories under the GHG Protocol.

Scope 1: Greenhouse gas emissions resulting from the direct use of fossil fuels

Scope 2: Greenhouse gas emissions resulting from secondary utilization, such as the purchase of electric power

*3. Scope: Olympus Corporation and its domestic and overseas subsidiaries (excluding certain North American production bases and small companies)